FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAchieve Life Sciences, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ACHV
Achieve Life Sciences, Inc. Stock AnalysisComprehensive stock analysis for Achieve Life Sciences, Inc. (ACHV) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisACHV
ACHV
Achieve Life Sciences, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ACHV
  1. Home
  2. Stocks
  3. Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc.

🇺🇸ACHV•NASDAQ

Achieve Life Sciences, Inc.

🇺🇸ACHV•NASDAQ
Market cap
$697.68M
Sentiment

Your view on ACHV

Mkt Cap
$697.68M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Achieve Life Sciences, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Richard A. B. Stewart
Headquarters
1040 West Georgia Street, Vancouver, BC, CA
Industry
Biotechnology
Sector
Healthcare
CEO
Richard A. B. Stewart
Headquarters
1040 West Georgia Street, Vancouver, BC, CA
Description

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom.

The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Achieve Life Sciences, Inc. from FRC's valuation model, read against the market price. ACHV last traded at $6.78; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Achieve Life Sciences, Inc.. Starting points for Achieve Life Sciences, Inc.: EPS -$1.32, beta 2.41 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Achieve Life Sciences, Inc.. Achieve Life Sciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Achieve Life Sciences, Inc.. Trailing twelve-month EPS for Achieve Life Sciences, Inc. stands at -$1.32. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 17, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$14.80

average of 5 firms, last 12 months

 

$14.80

Low $12.00

Median $13.00

High $18.00

 

Analyst Ratings

Buy4 ratings
  • Strong Buy0
  • Buy4
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrSep 2015Next QtrMar 2016Current YearFY Dec 2016Next YearFY Dec 2017
Avg. estimate-$0.18-$12.46-$1,870.00-$1,936.00
Low estimate-$0.22-$14.95-$4,360.83-$4,514.74
High estimate-$0.14-$9.97-$423.72-$438.68
No. of analysts151232
Year-ago EPS————
Growth————

Revenue Estimate

RevenueCurrent QtrSep 2015Next QtrMar 2016Current YearFY Dec 2016Next YearFY Dec 2017
Avg. estimate$7.16M$2.86M$4.78M$4.50M
Low estimate$5.73M$2.29M$1.94M$1.82M
High estimate$8.59M$3.43M$9.68M$9.11M
No. of analysts151212
Year-ago revenue————
Growth————
Recent analyst actions15 rating and price-target changes, latest Sep 29, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 17, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Achieve Life Sciences, Inc.. Achieve Life Sciences, Inc. has reported as a listed company since 1995. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ACHV13 companies · 8 funds
Compare ACHV with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • QNTMQuantum BioPharma Ltd.Biotechnology$9M

More Biotechnology companies

  • LGNDLigand Pharmaceuticals IncorporatedNASDAQ$6.0B
  • LGVNLongeveron Inc.NASDAQ$7M
  • LIANYLianBioOTC$10M
  • LIFSLife Stem Genetics Inc.OTC$9,168
  • LIMNLiminatus Pharma, Inc. Class A Common StockNASDAQ$4M
  • LIMNWLiminatus Pharma, Inc. WarrantsNASDAQ$941,853
  • LIPOLipella Pharmaceuticals Inc.NASDAQ$2M
  • LITSLite Strategy, Inc.NASDAQ$26M
  • LKFTLakefront Biotherapeutics N.V.NASDAQ$2.3B
  • LNAILunai Bioworks Inc.NASDAQ$829,677
  • LOBE.CNLobe Sciences Ltd.CNQ$10M
  • LOBEFLobe Sciences Ltd.OTC$8M

ETFs holding Achieve Life Sciences, Inc.

% of the fund

  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • VXFVanguard Extended Market ETF$30.2B in assets0.01%
  • VTWOVanguard Russell 2000 ETF$16.6B in assets0.02%
  • FESMFIDELITY ENHANCED SMALL CAP ETF$6.7B in assets0.03%
  • DWASInvesco Dorsey Wright SmallCap Momentum ETF$376M in assets0.32%
  • VFMOVanguard U.S. Momentum Factor ETF$1.9B in assets0.08%
  • VMO.TOVanguard Global Momentum Factor ETF$477M in assets0.05%
  • GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETF$1.0B in assets0.02%

Largest holders first, then the funds most concentrated in ACHV.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Achieve Life Sciences, Inc., and how their positions are changing. At a $697.7M market value, institutional positions materially move Achieve Life Sciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Achieve Life Sciences, Inc. executives and directors. Shares of Achieve Life Sciences, Inc. have traded between $1.84 and $5.78 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Achieve Life Sciences, Inc.. Coverage tracks Achieve Life Sciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Achieve Life Sciences, Inc.

ACHV Analysis
Fair
Past5
Growth2
Health3
Profit1
Value1

News

Latest Market News